Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder

Journal of Clinical Investigation

Volumn 123, Issue 9, 2013, Pages 3710-3712

  Broze Jr , George J ^a   Girard, Thomas J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR ALPHA; UNCLASSIFIED DRUG;

BINDING AFFINITY; BLEEDING DISORDER; BLEEDING TENDENCY; EAST TEXAS BLEEDING DISORDER; EXON; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; MOLECULAR INTERACTION; NONHUMAN; NOTE; PRIORITY JOURNAL; RNA SPLICING;

BLOOD COAGULATION DISORDERS, INHERITED; FACTOR V; HEMORRHAGIC DISORDERS; HUMANS; LIPOPROTEINS;

EID: 84883515148     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71220     Document Type: Note

References (15)

1. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor which inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood. 1988;71(2):335-343. (Pubitemid 18089519)
2. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A. 2006;103(9):3106-3111. (Pubitemid 43346432)
3. Ndonwi M, Tuley EA, Broze GJ Jr. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood. 2010;116(8):1344-1351.
4. Duckers C, et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood. 2008;112(9):3615-3623.
5. Castoldi E, Simioni P, Tormene D, Rosing J, Hackeng TM. Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma. J Thromb Haemost. 2010;8(2):294-300.
6. Ndonwi M, Girard TJ, Broze GJ Jr. The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va. J Thromb Haemost. 2012;10(9):1944-1946.
7. Monkovic DD, Tracy PB. Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin. J Biol Chem. 1990;265(28):17132-17140.
8. Bos MHA, Camire RM. A bipartite autoinhibitory region within the B-domain suppresses function in factor V. J Biol Chem. 2012;287(31):26342-26351.
9. Kuang SQ, et al. Characterization of a novel autosomal dominant bleeding disorder in a large kindred from east Texas. Blood. 2001;97(6):1549-1554.
10. A2440G causes east Texas bleeding disorder via TFPIα. J Clin Invest. 2013;123(9):3777-3787.
11. Huang Z-F, Wun T-C, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem. 1993;268(36):26950-26955. (Pubitemid 24006403)
12. Mast AE, Broze GJ Jr. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood. 1996;87(5):1845-1850. (Pubitemid 26068899)
13. Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry. 1990;29:1118-1128. (Pubitemid 20053831)
14. Hilden I, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood. 2012;119(24):5871-5878.
15. Gorczyca ME, et al. Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. J Thromb Haemost. 2012;10(8):1581-1590.